Physician profile
Tariq Shah
NPI 1750452116
$351,467.55
in general payments reported to CMS, 2019-2025
34 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $19K · 2021: $31K · 2022: $26K · 2023: $43K · 2024: $57K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Travel and Lodging: $25K · Consulting Fee: $10K · Food and Beverage: $9,005 · Honoraria: $1,500 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,192.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,002.00 |
| Travel and Lodging | $24,799.90 |
| Consulting Fee | $10,425.00 |
| Food and Beverage | $9,004.88 |
| Honoraria | $1,500.00 |
| Education | $391.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $138,489.31 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $53,228.59 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $52,060.91 | 2019 | |
| Apellis Pharmaceuticals, INC. | $30,964.32 | 2025 | Empaveli |
| Sanofi-Aventis U.S. LLC | $25,967.30 | 2020-2025 | |
| Veloxis Pharmaceuticals, INC. | $25,203.61 | 2019-2023 | Envarsus |
| Novartis Pharmaceuticals Corporation | $7,686.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,693.14 | 2024-2025 | Jardiance, Cyltezo |
| Lilly USA, LLC | $3,556.30 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $2,903.43 | 2023-2025 | Tarpeyo |
| Amgen INC. | $2,831.49 | 2022-2025 | Krystexxa, Tavneos, Evenity |
| Ardelyx, INC. | $366.72 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Opko Pharmaceuticals, LLC | $309.80 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $235.08 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.79 | 2022-2024 | Livtencity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $212.46 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $206.53 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $186.17 | 2023-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $169.16 | 2021-2024 | Rivfloza |
| Astrazeneca Pharmaceuticals Lp | $161.31 | 2019-2024 | Lokelma, Farxiga |
| Biogen, INC. | $149.24 | 2025 | |
| Glaxosmithkline, LLC. | $133.89 | 2023-2024 | Jesduvroq, Benlysta |
| Merck Sharp & Dohme LLC | $121.44 | 2025 | Prevymis |
| Horizon Therapeutics Plc | $108.22 | 2022 | |
| Fresenius USA Marketing, INC. | $101.88 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $77.79 | 2019-2020 | |
| Vifor Pharma, INC. | $42.54 | 2020-2022 | |
| La Jolla Pharmaceutical Company | $42.09 | 2025 | Giapreza |
| Allergan, INC. | $16.56 | 2019 | |
| Smith+Nephew, INC. | $13.56 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.